Table 2.
Covariates | Glimepiride (n = 68) | Sitagliptin (n = 65) | p value* |
---|---|---|---|
BMI (kg/m2) | 24.5 (24.2, 24.7) | 24.5 (24.3, 24.8) | 0.75 |
HbA1c (NGSP %) | 6.8 (6.7, 7.0) | 6.8 (6.7, 7.0) | 0.79 |
GA (%) | 17.4 (2.8) | 17.7 (2.6) | 0.30 |
ISI (l2/mmol pmol) | 15.8 (9.4, 20.8) | 17.3 (11.9, 23.5) | 0.046* |
Data are expressed as least-squares mean with 95 % confidence interval (CI) in BMI and HbA1c, means (SD) in GA, or median with interquartile range (IQR) in ISI
Analysis of variance (ANOVA) revealed a significant difference in the two groups
BMI body mass index, HbA1c hemoglobin A1c, GA glycated albumin, ISI insulin sensitivity index
*Comparison of the values after 52-week treatment between glimepiride and sitagliptin groups